S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia cuts oil output by 1 million barrels per day to boost sagging prices
WARNING to all American Investors (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia cuts oil output by 1 million barrels per day to boost sagging prices
WARNING to all American Investors (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia cuts oil output by 1 million barrels per day to boost sagging prices
WARNING to all American Investors (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia cuts oil output by 1 million barrels per day to boost sagging prices
WARNING to all American Investors (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
NASDAQ:SANA

Sana Biotechnology (SANA) Stock Forecast, Price & News

$6.43
+0.33 (+5.41%)
(As of 06/2/2023 ET)
Compare
Today's Range
$6.16
$6.70
50-Day Range
$3.11
$7.53
52-Week Range
$2.99
$9.55
Volume
1.25 million shs
Average Volume
1.48 million shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Sana Biotechnology MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
55.5% Upside
$10.00 Price Target
Short Interest
Bearish
33.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Sana Biotechnology in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$2.80 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

706th out of 980 stocks

Biological Products, Except Diagnostic Industry

112th out of 163 stocks


SANA stock logo

About Sana Biotechnology (NASDAQ:SANA) Stock

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Receive SANA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

SANA Stock News Headlines

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 5.6%
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
Sana Biotechnology (NASDAQ:SANA) Trading Down 6.2%
Disturbing Truth About Biden's New Program To Seize Your Cash
A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Sana Biotechnology (NASDAQ:SANA) Shares Up 8.5%
See More Headlines

SANA Price History

SANA Company Calendar

Last Earnings
3/16/2023
Today
6/04/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SANA
Fax
N/A
Employees
383
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+55.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-269,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.24 per share

Miscellaneous

Free Float
123,710,000
Market Cap
$1.23 billion
Optionable
Not Optionable
Beta
0.71

Key Executives

  • Dr. Steven D. Harr M.D. (Age 53)
    Pres, CEO & Director
    Comp: $1.19M
  • Dr. Richard C. Mulligan Ph.D. (Age 68)
    Exec. Vice Chairman & Head of SanaX
  • Mr. Nathan Hardy M.B.A. (Age 47)
    Exec. VP & CFO
    Comp: $683.49k
  • Dr. Sunil Agarwal M.D. (Age 53)
    Exec. VP, Head of Devel. & Chief Medical Officer
    Comp: $728.45k
  • Brittany Mccleery
    Accounting Mang.
  • Dr. Edward Rebar Ph.D. (Age 55)
    Sr. VP & CTO
  • Mr. Bernard J. Cassidy J.D. (Age 68)
    Exec. VP & Gen. Counsel
  • Ms. Robin Andrulevich (Age 57)
    Exec. VP & Chief People Officer
  • Mr. Paul Brunetta M.D.
    Sr. VP and Head of Clinical & Translational Science
  • Ms. Donna Dambach D.V.M.
    Ph.D., Sr. VP & Head of Devel. Sciences













SANA Stock - Frequently Asked Questions

Should I buy or sell Sana Biotechnology stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SANA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SANA, but not buy additional shares or sell existing shares.
View SANA analyst ratings
or view top-rated stocks.

What is Sana Biotechnology's stock price forecast for 2023?

3 analysts have issued twelve-month price targets for Sana Biotechnology's stock. Their SANA share price forecasts range from $6.00 to $13.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 55.5% from the stock's current price.
View analysts price targets for SANA
or view top-rated stocks among Wall Street analysts.

How have SANA shares performed in 2023?

Sana Biotechnology's stock was trading at $3.95 at the beginning of the year. Since then, SANA shares have increased by 62.8% and is now trading at $6.43.
View the best growth stocks for 2023 here
.

When is Sana Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our SANA earnings forecast
.

How were Sana Biotechnology's earnings last quarter?

Sana Biotechnology, Inc. (NASDAQ:SANA) posted its quarterly earnings results on Thursday, March, 16th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.01.

When did Sana Biotechnology IPO?

(SANA) raised $322 million in an initial public offering on Thursday, February 4th 2021. The company issued 15,000,000 shares at $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO.

What is Sana Biotechnology's stock symbol?

Sana Biotechnology trades on the NASDAQ under the ticker symbol "SANA."

Who are Sana Biotechnology's major shareholders?

Sana Biotechnology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (5.68%), FMR LLC (4.78%), BlackRock Inc. (4.07%), State Street Corp (2.97%), Price T Rowe Associates Inc. MD (2.36%) and JPMorgan Chase & Co. (1.28%). Insiders that own company stock include Christian Hordo, James J Macdonald, Joshua H Bilenker, Patrick Y Yang and Ventures Fund V Gener Flagship.
View institutional ownership trends
.

How do I buy shares of Sana Biotechnology?

Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sana Biotechnology's stock price today?

One share of SANA stock can currently be purchased for approximately $6.43.

How much money does Sana Biotechnology make?

Sana Biotechnology (NASDAQ:SANA) has a market capitalization of $1.23 billion. The company earns $-269,480,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How many employees does Sana Biotechnology have?

The company employs 383 workers across the globe.

How can I contact Sana Biotechnology?

Sana Biotechnology's mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The official website for the company is sana.com. The company can be reached via phone at 206-701-7914 or via email at investor.relations@sana.com.

This page (NASDAQ:SANA) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -